Avalyn Pharma Inc.'s Lock-Up Period Set To End on October 27th (NASDAQ:AVLN)

Key Points

• Avalyn Pharma’s lock-up period expires October 27, allowing insiders and major shareholders to sell shares. The lock-up covers 16.7 million shares issued in the company’s $300 million public offering.
• Analyst sentiment is mixed but leans positive: Avalyn has an average “Moderate Buy” rating and a consensus price target of $60, compared with a recent share price of $23.33.
• The stock has declined 1.4% and trades near its 12-month low, while recent institutional investors—including Montanara Capital, Braidwell, and State Street—have established sizable positions.

Avalyn Pharma's (NASDAQ:AVLN - Get Free Report) lock-up period will expire on Tuesday, October 27th. Avalyn Pharma had issued 16,666,667 shares in its public offering on April 30th. The total size of the offering was $300,000,006 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Weiss Ratings initiated coverage on Avalyn Pharma in a research report on Thursday, August 13th. They set a "sell (d+)" rating on the stock. Raymond James Financial started coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They issued an "outperform" rating and a $60.00 price objective on the stock. Finally, Wall Street Zen cut Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $60.00.

Avalyn Pharma Trading Down 1.4%

NASDAQ:AVLN opened at $23.33 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The stock has a market cap of $1.03 billion and a price-to-earnings ratio of -1.02. The company has a 50-day moving average price of $32.28. Avalyn Pharma has a 12-month low of $22.68 and a 12-month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. On average, equities research analysts forecast that Avalyn Pharma will post -3.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avalyn Pharma

A number of large investors have recently added to or reduced their stakes in AVLN. Bank of New York Mellon Corp purchased a new position in Avalyn Pharma in the second quarter valued at about $1,321,000. Montanova Capital LLC purchased a new position in Avalyn Pharma during the 2nd quarter valued at about $82,402,000. Braidwell LP purchased a new stake in Avalyn Pharma in the 2nd quarter worth approximately $26,382,000. Finally, State Street Corp acquired a new stake in Avalyn Pharma during the second quarter valued at $10,501,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company's primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company's development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.